Alexander Fleming, MD

Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices, and digital health technologies. He is also President and co-founder of Kitalys Institute. Dr. Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow.

At the US Food and Drug Administration from 1986-98, led many landmark drug and biotech approvals and innovations as well as represented the Agency at the ICH and WHO Geneva, where he was posted. Dr. Fleming has authored diverse scientific articles, books, and book chapters. He has served on many corporate and advisory boards to academic and commercial institutions and professional societies.

Dr. Fleming coined the term, Metabesity, which refers to the constellation of chronic diseases, cancer, and the aging process itself, all which share common metabolic root causes and potential for shared preventions. He organized the first Congress on Metabesity in London in 2017, which has since been followed by yearly conferences. He founded Kitalys Institute to support the conference [now called the Targeting Healthy Longevity Conference] and related objectives.